Ciba-geigy Corporation

Incyte Pharmaceuticals, Inc.

Burroughs Wellcome Co.

Novartis Corporation

Novartis Corproation

Karel Gerrit Odink

Lajos Tarcsay

Nico Cerletti

Walter Wiesendanger

Clemens Sorg

Josef Bruggen

Roger Clerc

Christiane DeWolf-Peeters

Jan Delabie

Anthony A Holder

Sergio Gloor

Valentina Riveros-Moreno

Jasbir S Sandhu

Michael J Lockyer

The invention concerns polypeptides with an apparent molecular weight of around 160 kD which are mediators or precursors for mediators of inflammation, derivatives thereof such as mutants and fragments, processes for their preparation, DNAs and hybrid vectors coding for the polypeptides and derivatives and host cells transformed with such hybrid vectors, polyclonal and monoclonal antibodies specific for the polypeptides or their derivatives and antibody derivatives as well as diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.

Cytokine which mediates inflammation

The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for those polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to those polypeptides, and diagnostic methods for inflammatory conditions and cystic fibrosis.

DNAS encoding human macrophage migration inhibition factor related

The invention relates to a neurite-promoting factor released by glial cells, to related proteins and fragments thereof retaining their neurite-promoting activity, to DNAs coding for the amino acid sequence of the neurite-promoting factor and fragments thereof, to hybrid vectors containing such DNAs, to hosts transformed with such a hybrid vector, to processes for the preparation of the DNAs, vectors and transformed hosts, to processes for the manufacture of the neurite-promoting factor, related proteins and its fragments, and to their use in the treatment of lesions in the nervous system.

Method of treating lesions in a nervous system

The present invention relates to the P.195 gene of Plasmodium falciparum and, more specifically, to the cloning of that gene. The invention further relates to a method of producing the P.195 protein using the cloned gene. The invention also relates to a vaccine comprising the P.195 protein and to the use of same in the prophylaxis of malaria.

Cloning of a malarial gene

The invention concerns polypeptides with an apparent molecular weight of around 160 kD which are mediators or precursors for mediators of inflammation, derivatives thereof such as mutants and fragments, processes for their preparation, DNAs and hybrid vectors coding for said polypeptides and derivatives and host cells transformed with such hybrid vectors, polyclonal and monoclonal antibodies specific for said polypeptides or their derivatives and antibody derivatives as well as diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.

The invention concerns polypeptides related to human macrophage migration inhibition factor, in particular the polypeptides called MRP-8 and MRP-14, processes for their preparation, mRNAs, DNAs and hybrid vectors coding for said polypeptides, hosts transformed with such a hybrid vector, monoclonal and polyclonal antibodies to said polypeptides , and diagnostic methods for inflammatory conditions and cystic fibrosis.

Antibodies which bind to novel lymphokine related peptides

Growing community of inventors

Rheinfelden, Switzerland

Karel Gerrit Odink